Simulect (basiliximab) / Novartis 
Welcome,         Profile    Billing    Logout  

38 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Simulect (basiliximab) / Novartis
ACTRN12611001224910: REmoval Of Tacrolimus For Sirolimus Following Thymoglobulin Induction On The Development of REgulatory T Cells in Kidney Transplant Patients

Not yet recruiting
4
30
 
Department of Health, Genzyme Australia, Pfizer Australia
Development of circulating regulatory T cells, Kidney transplant function, complications and biopsy, Cardiovascular health, Metabolic outcomes (glucose abnormality), Clinical significant infections and cancers
 
 
2010-021075-89: A MULTICENTER, THREE ARM, RANDOMIZED, OPEN LABEL CLINICAL STUDY TO COMPARE RENAL FUNCTION IN LIVER TRANSPLANT RECIPIENTS RECEIVING AN IMMUNOSUPPRESSIVE REGIMEN OF ADVAGRAF® (IMMEDIATELY OR DELAYED POST-TRANSPLANT) AND MMF WITH OR WITHOUT A MONOCLONAL ANTI-IL2R ANTIBODY (BASILIXIMAB)

Ongoing
4
150
Europe
Capsule, hard, Powder and solvent for solution for injection, Advagraf, Simulect
Astellas Pharma Europe Ltd.
RENAL FUNCTION IN LIVER TRANSPLANT RECIPIENTS RECEIVING AN IMMUNOSUPPRESSIVE REGIMEN OF ADVAGRAF® (IMMEDIATELY OR DELAYED POST-TRANSPLANT) AND MMF WITH OR WITHOUT SIMULECT
 
 
2006-000830-11: A randomised prospective trial of tacrolimus-based steroid avoidance in renal transplantation with either alemtuzumab induction or, basiliximab induction and mycophenolate mofetil maintenance therapy

 
4
120
Europe
MabCampath, Simulect, CellCept, MabCampath, Simulect, CellCept, MabCampath, Simulect, CellCept
Leeds Teaching Hospitals NHS Trust
MabCampath / Alemtuzumab will be used as part of the immunosuppression regime following renal transplant.
 
 
2013-000766-11: Etude pilote, prospective, multicentrique, randomisée, en ouvert, comparant deux protocoles d’immunosuppression utilisant en traitement d’induction : soit un anticorps monoclonal antirécepteur de l’Interleukine 2 (Simulect®), soit des globulines antilymphocytaires (ATG® Frésénius), associés à une trithérapie Prograf®, Myfortic® et corticoïdes, pour la prévention du rejet chez les adultes transplantés rénaux immunisés de novo.

Ongoing
4
60
Europe
ATG® frésénius, Simulect® (Basiliximab), ATG® frésénius, Simulect® (Basiliximab)
CHU Toulouse, FRESENIUS, NOVARTIS
Prévention du rejet chez les adultes transplantés rénaux
 
 
2010-019337-10: Estudio piloto abierto, aleatorizado (2:1), prospectivo y unicentrico para evaluar el rechazo agudo y la función renal de una pauta inmunosupresora libre de fármacos anticalcineurínicos frente a un regimen convencional (basado en fármacos anticalcineurinicos) en receptores de un trasplante renal de riesgo estándar. Estudio piloto abierto, aleatorizado (2:1), prospectivo y unicentrico para evaluar el rechazo agudo y la función renal de una pauta inmunosupresora libre de fármacos anticalcineurínicos frente a un regimen convencional (basado en fármacos anticalcineurinicos) en receptores de un trasplante renal de riesgo estándar.

Ongoing
4
30
Europe
MICOFENOLATO MOFETIL, TACROLIMUS, TIMOGLOBULINA 5mg/ml Polvo para solución para perfusión, PRIVIGEN 100 mg/ml solución para perfusión, RAPAMUNE 1 mg comprimidos recubiertos, SIMULECT 20 mg polvo y disolvente para sol. iny. o sol. para perfusión, CELLCEPT 250 MG CAPSULAS, CELLCEPT 500 MG COMPRIMIDOS, CELLCEPT 500MG, POLVO PARA CONCENTRADO PARA SOL. PARA PERFUSION, RAPAMUNE 1 mg/ml solución oral, TIMOGLOBULINA 5mg/ml Polvo para solución para perfusión, PRIVIGEN 100 mg/ml solución para perfusión, RAPAMUNE 1 mg comprimidos recubiertos, SIMULECT 20 mg polvo y disolvente para sol. iny. o sol. para perfusión, CELLCEPT 250 MG CAPSULAS, CELLCEPT 500 MG COMPRIMIDOS, CELLCEPT 500MG, POLVO PARA CONCENTRADO PARA SOL. PARA PERFUSION, RAPAMUNE 1 mg/ml solución oral
SERVICIO NEFROLOGIA HOSPITAL UNIVERSITARIO DE BELLVITGE, Pfizer, Behring
END STAGE RENAL DISEASE-KIDNEY TRANSPLANTATION INSUFICIENCIA RENAL TERMINAL- TRASPLANTE RENAL
 
 
ChiCTR1800017266: A single center prospective study comparing the effects of induction therapy in Chinese donation after cardiac death (DCD) patients between rabbit anti-human thymocyte immunoglobulin (Thymoglobulin) and basiliximab ( Simulect)

Recruiting
4
80
 
rATG standard dose (5.0-6.0 mg/kg) ;rATG standard dose (4.0-5.0 mg/kg) ;Basiliximab standard dose
General Hospital of Chinese People's Armed Police Forces; General Hospital of Chinese People's Armed Police Forces, Hospital
Kidney Transplantation
 
 
ChiCTR1800019322: A prospective, randomized, controlled trial for the efficacy of baliximab induction in the blood-group incompatible peditric liver transplantation

Not yet recruiting
4
50
 
Basiliximab induction ;without Basiliximab induction
Tianjin First Central Hospital; Tianjin First Central Hospital, self-collected
pediatric liver transaplantation
 
 
NCT03789006: Antithymocyte Globulin and Azathioprine Versus Basiliximab and Mycophenolate Mofetil in Living Donor Kidney Transplantation

Recruiting
4
300
RoW
Antithymocyte Immunoglobulin (Rabbit), grafalon, Interleukin 2 Receptor Antagonist, Basiliximab
University of Khartoum, National Center for Kidney Diseases and Surgery
Kidney Transplant Rejection
03/22
03/24
NCT04009525: Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major: A Multicenter, Prospective Clinical Study

Recruiting
4
800
RoW
Busulfan, Bu, Cyclophosphamide, Cy, Fludarabine, Flu, Thymoglobulin, ATG, cyclosporine A, CsA, Mycophenolate mofetil, MMF, Tacrolimus, FK506, Methotrexate, MTX, Basiliximab, Simulect, Ruxolitinib
First Affiliated Hospital of Guangxi Medical University, Peking University People's Hospital, Ruijin Hospital, The 923th Hospital of People's Liberation Army, Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou General Hospital, Hainan General Hospital, The Affiliated Hospital Of Guizhou Medical University, The First People's Hospital of Yunnan
Thalassemia Major
05/22
05/23
NCT05021276: Basiliximab Combined With Ruxolitinib as Second-line Treatment of Grade 3-4 Steroid-resistant aGVHD

Recruiting
4
50
RoW
Ruxolitinib, basiliximab
The First Affiliated Hospital of Soochow University, Soochow Hopes Hematonosis Hospital, Huai'an Second People's Hospital
Safety and Efficacy
07/22
12/22
NCT03794492: Impact of Lymphocyte Anti-metabolite Immunosuppressions on Donor-Specific Anti-HLA Antibody and Kidney Graft Outcome

Completed
4
169
RoW
Mycophenolate mofetil 500mg Tab. or 250mg Cap., Myrept® Cap./Tab., Tacrolimus, Methylprednisolone/prednisolone, Basiliximab
Chong Kun Dang Pharmaceutical
Kidney Transplant
07/22
04/23
SIMPLE, NCT04773392: Simplified IMmunosuppressive Protocol Utilizing Low Dose EnvarsusXR

Recruiting
4
80
US
Twice-daily Tacrolimus, Once-daily envarsus XR, Induction Immunosuppression with Basiliximab or Rabbit Anti Thymoglobulin (rATG), Methylprednisolone, prednisone, Steroids, Mycophenolate mofetil (MMF) or Mycophenolic acid (MPA), Twice a day anti-metabolite, Azathioprine, Once a day anti-metabolite
University of Southern California, Veloxis Pharmaceuticals
Kidney Transplantation, Kidney Transplant Rejection
02/25
02/25
NCT04404127: Standard Induction With Basiliximab Versus No-Induction in Low Immunological Risk Kidney Transplant Recipients

Recruiting
4
140
RoW
Basiliximab 20 milligram [Simulect], Normal Saline
King Faisal Specialist Hospital & Research Center
Kidney Transplantation
05/23
05/25
NCT04104438: Examination of Immunosuppression Adjustment Impact on Kidney Function in Liver Transplant

Recruiting
4
90
US
Basiliximab 20 MG, Everolimus
Fady M Kaldas, M.D., F.A.C.S.
Asses Immunosuppression Modulation on Renal Recovery Post LT
12/23
12/23
NCT06066840: Vedolizumab, Anti-CD25 Antibody, Rapid Reduction of Glucocorticoids for SR-aGVHD With Gastrointestinal Involvement

Recruiting
4
45
RoW
Basiliximab, anti-CD25 monoclonal antibody, Vedolizumab, anti-α4β7 monoclonal antibody
The First Affiliated Hospital of Soochow University, The First Affiliated Hospital with Nanjing Medical University, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Affiliated Hospital of Nantong University
Safety and Efficacy
07/25
12/25
2009-018174-54: MERIDIAN: A 12-month prospective, open-label, randomized, multicenter,parallel-group study to evaluate the efficacy, safety andtolerability of a Myfortic®-based regimen in the conversion from aCNI to everolimus in de novo transplant recipients of ExpandedCriteria of Donor kidneys

 
3/4
35
Europe
Myfortic, Certican, Sandimmun Neoral, Simulect, ERL080, Myfortic, Certican, Sandimmun Neoral, Simulect, Myfortic, Certican, Sandimmun Neoral, Simulect
Novartis Pharma Services AG, Novartis Farmacéutica, S.A., Novartis Services AG
de novo transplant recipients of Expanded Criteria Donor (ECD) kidneys
 
07/10
NCT00856466: Extension Study to CRAD001A1202

Active, not recruiting
3
110
Japan
everolimus, mycophenolate mofetil
Novartis
Renal Transplant
12/12
 
2005-000380-26: A 12 month, multicenter, randomized, parallel, open-label study, to evaluate renal function and efficacy of Certican® (everolimus) with Simulect® (basiliximab) and cyclosporine discontinuation at 3 month post-transplant vs minimization, in de novo kidney transplant recipients

Ongoing
3
168
Europe
Certican®, RAD001, Certican®, Certican®
Novartis Farmacéutica S.A.
Renal Transplant
 
 
NCT00679042: Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol

Active, not recruiting
3
21
US
Islets of Langerhans transplantation, Islets of Langerhan (Islets), Basiliximab (Simulect®), Tacrolimus (Prograf®), Sirolimus (Rapamune®), Etanercept(Enbrel®), Exenatide (Byetta®)
CellTrans Inc.
Type 1 Diabetes Mellitus
07/17
06/26
NCT04738981: Efficacy and Safety of UC-MSCs for the Treatment of Steroid-resistant aGVHD Following Allo-HSCT

Completed
3
130
RoW
UC-MSC, Umbilical cord-derived mesenchymal stem cells, Anti-CD25 mAb, Basiliximab
Peking University People's Hospital, Southern Medical University, China, Third Military Medical University, Sun Yat-sen University
Graft Vs Host Disease
05/22
05/23
INSTEAD, NCT05385432: Induction in Sensitized Kidney Transplant Recipients Without Pre-existing Donor-specific antiboDies

Not yet recruiting
3
244
NA
Rabbit Anti thymocyte globulin (rATG), Maintenance immunosuppressive regimen is the same in experimental and control groups combining tacrolimus, mycophenolate mofetil (MMF) or enteric-coated mycophenolate sodium (EC-MPS) and steroids, Basiliximab
University Hospital, Tours
Renal Transplant Rejection, Induction Therapy
03/27
03/30
NCT01469390: Pharmacodynamics, Efficacy, Safety of Basiliximab 40 or 80 mg Combined With CsA or Everolimus, in Low Risk de Novo Renal Transplant Recipients

Not yet recruiting
2
50
Europe
Basiliximab, Simulect
Novartis Pharmaceuticals
Renal Transplantation
04/13
 
NCT02464878: Multicenter Trial of the Effect of AAT on Islet Transplant Engraftment and Durability After Renal Transplant

Completed
2
2
US
Alpha 1-Antitrypsin, Glassia, Islet Transplantation, Thymoglobulin, Antithymocyte Globulin, Basiliximab, Etanercept, Enbrel
Massachusetts General Hospital, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), University of Iowa
Kidney Transplant, Type 1 Diabetes
11/22
12/22
NCT04337593: Combination of Basiliximab and Pegaspargase in the Treatment of ENKTCL

Not yet recruiting
2
20
NA
Basiliximab, anti-CD25 antibody, Pegaspargase
Beijing Tongren Hospital
Extranodal NK/T-cell Lymphoma
05/22
12/22
FWCSWG-IL-2, NCT05013034: Exploratory Regimen of Basiliximab for Treatment of Pulmonary Cytokine Storm in SARS-CoV-2 Hospitalized Adult Patients

Not yet recruiting
2
300
NA
Basiliximab Injection, Simulect, Placebo
Fort Worth Clinical Sciences Working Group, TCU and UNTHSC School of Medicine
SARS-CoV-2 Acute Respiratory Disease, SARS-CoV2 Infection, Cytokine Storm
10/22
12/22
NCT06480630: Effectiveness and Safety of a Single-Center Clinical Study on a CD25 Monoclonal Antibody-Containing GVHD Prophylaxis Scheme to Reduce the Incidence of Severe Acute GVHD After Umbilical Cord Blood Transplantation for Malignant Hematologic Diseases

Not yet recruiting
2
39
RoW
Basiliximab
Anhui Provincial Hospital
Acute Graft Versus Host Disease, Malignant Hematologic Neoplasm
06/26
06/27
NCT04871607: Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma

Recruiting
2
33
US
Basiliximab, SDZ-CHI-621, Simulect, Carmustine, BCNU, Becenum, Becenun, BiCNU, Bis(chloroethyl) Nitrosourea, Bis-Chloronitrosourea, Carmubris, Carmustin, Carmustinum, FDA 0345, N,N'-Bis(2-chloroethyl)-N-nitrosourea, Nitrourean, Nitrumon, SK 27702, SRI 1720, WR-139021, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP-16, VP-16-213, VP16, Genetically Engineered Hematopoietic Stem Progenitor Cells, Genetically Engineered HSPCs, Recombinant Granulocyte Colony-Stimulating Factor, Recombinant Colony-Stimulating Factor 3, rhG-CSF, Yttrium Y 90 Basiliximab, 90Y Basiliximab, Yttrium Y 90-DOTA-Basiliximab
City of Hope Medical Center, National Cancer Institute (NCI)
Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
10/27
10/27
ACTRN12605000802606: SHIRT (Salvage Hodgkins Immunoradiotherapy)

Recruiting
1/2
10
 
South Metropolitan Area Health Service WA, Physician Sponsored
Lymphoproliferative Malignancies (Relapsed or Refractory)
 
 
NCT02342782: Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin Lymphoma

Active, not recruiting
1
20
US
Yttrium Y 90 Basiliximab, 90Y Basiliximab, Carmustine, FDA 0345, BCNU, BiCNU, Etoposide, Lastet, VP-16, Cytarabine, CHX-3311, U-19920, Ara-C, Cytosar, Melphalan, Alkeran, L-PAM, Autologous Hematopoietic Stem Cell Transplantation, Autologous Stem Cell Transplantation, Laboratory Biomarker Analysis, Pharmacological Study, pharmacological studies
City of Hope Medical Center, National Cancer Institute (NCI)
Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma
09/20
12/24
NCT01476839: Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma

Active, not recruiting
1
25
US
basiliximab, SDZ-CHI-621, Simulect, carmustine, BCNU, BiCNU, bis-chloronitrosourea, etoposide, EPEG, VP-16, VP-16-213, cytarabine, ARA-C, arabinofuranosylcytosine, arabinosylcytosine, Cytosar-U, cytosine arabinoside, melphalan, Alkeran, CB-3025, L-PAM, L-phenylalanine mustard, L-Sarcolysin, pharmacological study, pharmacological studies, laboratory biomarker analysis, autologous hematopoietic stem cell transplantation, yttrium Y 90-labeled basiliximab, 90Y basiliximab
City of Hope Medical Center, National Cancer Institute (NCI)
Recurrent Adult Hodgkin Lymphoma
07/21
12/24
NCT01526096: Stem Cell Transplantation for Patients With Multiple Myeloma

Active, not recruiting
1
15
US
G-CSF, Plerixafor, Apheresis, Melphalan, Alkeran, Stem cell re-infusion, Basiliximab, Simulect, CliniMACS CD25 microbeads and cell sorter
University of Chicago
Myeloma
09/25
09/25
NCT05139004: 90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome

Recruiting
1
12
US
Allogeneic Hematopoietic Stem Cell Transplantation, Allogeneic, Allogeneic Hematopoietic Cell Transplantation, Allogeneic Stem Cell Transplantation, HSC, HSCT, Stem Cell Transplantation, Allogeneic, Basiliximab, SDZ-CHI-621, Simulect, Fludarabine Phosphate, 2-F-ara-AMP, 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-, Beneflur, Fludara, SH T 586, Indium In 111-DOTA-Basiliximab, 111In-DOTA-Basiliximab, Melphalan, Alanine Nitrogen Mustard, CB-3025, L-PAM, L-Phenylalanine Mustard, L-Sarcolysin, L-Sarcolysin Phenylalanine mustard, L-Sarcolysine, Melphalanum, Phenylalanine Mustard, Phenylalanine Nitrogen Mustard, Sarcoclorin, Sarkolysin, WR-19813, Palifermin, Growth Factor, Recombinant Human Keratinocyte, Kepivance, Keratinocyte Growth Factor, Recombinant Human, Recombinant Human Keratinocyte Growth Factor, rhKGF, rhu Keratinocyte Growth Factor, Total Lymphoid Irradiation, TLI, Total Marrow Irradiation, Yttrium Y 90 Basiliximab, 90Y Basiliximab, Yttrium Y 90-DOTA-Basiliximab
City of Hope Medical Center, National Cancer Institute (NCI)
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome, Secondary Acute Myeloid Leukemia
12/24
12/24
ChiCTR-OCH-12002890: Treatment of Severe Steroid-refractory Acute Graft-versus-host Disease in Allogeneic Hematopoietic Stem Cell Transplantation

Completed
N/A
60
 
Treatment with Etanercept and Basiliximab ;Basiliximab ;Etanercept
the First Affiliated Hospital of Zhejiang University School of Medicine; None, Self-funding
hematologic malignacy
 
 
NCT01049633: B-Lymphocyte Immunotherapy in Islet Transplantation for Initial Islet Graft Failure

No Longer Available
N/A
US
Allogeneic Pancreatic Islet Cells, Sirolimus, Basiliximab, Tacrolimus, Antibacterial, Antifungal, and Antiviral Prophylaxis, Trimethoprim/sulfamethoxazole, Septra SS, Clotrimazole, Mycelex Troche, Valganciclovir, Valcyte, Heparin, Anticoagulation and Hematological Agent, Enoxaparin, Lovenox; Anticoagulation and Hematological Agent, Pentoxifylline, Aspirin, ASA
National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type 1 Diabetes Mellitus
 
 
ChiCTR1900028311: The study of efficacy and safety of basiliximab in the treatment of steroid-resistant graft-versus-host disease after allogeneic hematopoietic stem cell transplantation

Recruiting
N/A
288
 
None
Peking University People's Hospital; Peking University People's Hospital, the Foundation for Innovative Research Groups of the National Natural Science Foundation of China
Hematological disease
 
 
PINK, NCT06087003: Pediatric Induction Therapy in Kidney Transplantation

Completed
N/A
958
RoW
Basiliximab Injection, Simulect, rabbit ATG, Thymoglobuline
Gang Chen, Zhejiang University, First Affiliated Hospital, Sun Yat-Sen University, The First Affiliated Hospital of Zhengzhou University, Changhai Hospital
Kidney Transplant Rejection, Pediatric Kidney Disease
07/22
09/23
ONSET, NCT06374095: 1 vs 7 RATG Infusions in Renal Transplantation

Not yet recruiting
N/A
75
Europe
RATG, Thymoglobulin, Basiliximab, Simulect
Mario Negri Institute for Pharmacological Research
Kidney Replacement
06/25
06/25
MERRLIN, NCT04736381: Impact of the Microbiota on the Likelihood of Renal Graft Rejection

Not yet recruiting
N/A
70
NA
Belatacept Injection [Nulojix], Simulect, Mycophenolate mofetil, Steroid
Institut National de la Santé Et de la Recherche Médicale, France
Kidney Transplant Rejection
09/23
09/24

Download Options